INTRODUCTION
Cellular mediated immune responses to brucellosis drive a broad range of manifestations of the disease that vary from subclinical infection (more common with Brucella abortus) to undulant fever, to focal pyogenic infection, to chronic fatigue syndromelike illness (Yingst and Hoover, 2003; Yang et al., 2005) . However, the molecular mechanisms that determine the variable manifestations of Brucella infection remain to be elucidated. Information on acquired immunity to human brucellosis has been accumulated through observational studies of naturally infected hosts (cattle, goats), experimental models (mice), and observations of human disease. Three predominant Brucella species are seen frequently in human infections: B. melitensis, B. abortus, and B. suis. Of these three species, B. melitensis infections are most commonly seen in humans and seem to be the most pathogenic (Pappas et al., 2005) . In the United States, domesticated cattle, which are potential reservoirs for the organism, are vaccinated against B. abortus (RB51 or S19); elsewhere (in the Middle East and Latin America), goats and sheep may be vaccinated with Rev-1, an attenuated strain of B. melitensis. Currently available veterinary vaccines are comprised of live-attenuated organisms but are unacceptable in humans because they cause clinical disease (Kinikli et al., 2005; Durward et al., 2010) .
Brucellosis can occur in several forms: acute/subacute (associated with positive blood cultures, high titer agglutination serologies), focal (blood culture negative, serologically variable, and Vrioni et al., 2008) . Brucella spp. LPS is also composed of longer carbon chains (C28) as apposed to the usual 12-16 carbons in the LPS from Enterobacteriaceae. In addition, Brucella spp. produce proteins (e.g., Vi antigen), which create a capsule around the LPS, therefore limiting it to have contact with TLR4 receptors (Lapaque et al., 2005; Tsolis et al., 2008) . In addition, the domain for the flagellin protein in Brucella spp. does not stimulate TLR5 receptors, and is another way for the bacteria to evade the immune system during early infection (Tsolis et al., 2008) . These areas are conserved in all Brucella spp. and to others in the same family to evade detection by the immune system during the infection and possibly allowing the bacteria to persist in the reticuloendothelial system (Tsolis et al., 2008; Barquero-Calvo et al., 2009) . After initial encounter with Brucella antigens, APCs produce interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and gamma-interferon (IFN-γ) initiating innate immune responses (including natural killer cells) that may limit the initial spread of organisms. Infected APC in which organisms residing within unactivated phagolysosomes are likely to present some subset of peptidic Brucella antigens (hitherto unknown) to CD4+ and CD8+ cells, and thus inducing a TH 1 response associated with IFN-γ release. The functional consequences of antigen-specific IFN-γ release is unclear but does not lead to elimination of organisms during active, symptomatic infection and likely results in clinical symptomatology (i.e., fever, sweating, weight loss). Clonal T cell expansion is initiated with production of interleukin-2 (IL-2) and interleukin-12 (IL-12), which initiates a CD8+ cytotoxic response on Brucella-infected cells. Infected macrophages produce IL-12 and IFN-γ which regulate antigen presentation and may contribute to the limitation of intracellular bacterial replication through unknown mechanisms (Akbulut et al., 2005) . Data also suggest that Brucella spp. also modify the initial immune response once phagocytosed into APCs. To survive within APCs, Brucella use certain gene products to subvert certain phagocyte intracellular processes, particularly phagosomelysosome fusion which would be associated with bacterial killing. One way that the organism survives within APCs is through Brucella-containing vacuoles (BCVs), which the organism secretes Sar1, a critical protein which allows the organism to replicate within these vacuoles (Celli et al., 2005) . CD64, also known as FcγRI, is a macrophage-expressed gene whose expression is down-regulated in B. melitensis infections (Lapaque et al., 2005) , reflecting the reduction of antigen processing in Brucella-infected APCs and possibly inhibiting the killing of infected cells initiated by CD4+ and CD8+ T cells. This mechanism may be important for decreasing superoxide and reactive nitrogen compounds as another pathogen-associated localized immunosuppression. Other gene products such as cystatin C, serpina3c, and Gas2 (natural peptidase inhibitors) appear to alter macrophage chemotaxis, cell migration, and proliferation, which may further allow Brucella to avoid immune surveillance and lead to enhanced multiplication (Lapaque et al., 2005) . Decreased transcription of Cyp4a10 is thought to be associated with the reduction of oxidative stress that creates an environment conducive to bacterial proliferation. Prkca is another macrophage-associated gene potentially modulated during Brucella infection, who functions includes regulating phagosome-lysosome fusion and intracellular vesicle and reactive oxygen species (ROS) generation. Prkca expression is dramatically reduced in Brucella-infected macrophages, and interestingly, has been shown to be regulated by other intracellular pathogens such as Salmonella, Leishmania, and Legionella. All these mechanisms contribute to allowing Brucellae to survive within the intracellular environment, and evade not only the innate immunity, but CD4+-and CD8+-mediated host cell killing (Covert et al., 2009) .
Alteration of T cell function may be key to explaining the clinico-pathological manifestations of chronic or relapsing brucellosis. Specifically, a decreased TH 1 cytokine response by APCs (with decreased activation of cytotoxic T cells via IFN-γ, IL-12, and possibly IL-17 (Pasquevich et al., 2010) , and toward a TH 2 response (which decreases phagocyte function and reduced cytotoxic response via IL-4, IL-5, and IL-10; Jimenez de Bagues et al., 2005) . These infected cells fail to produce IFN-γ, and decrease clonal expansion of Brucella-specific CD4+ T cells. Subsequently, Brucella-specific CD8+ T cells would not initiate destruction of infected cells by perforin and granzyme injection (cell lysis) or through stimulation of FAS ligand (cellular apoptosis; Yingst and Hoover, 2003; Skendros et al., 2008) . Based on these considerations, the unusual and diverse manifestations of chronic and relapsing brucellosis could be related to several potential immunopathogenic mechanisms: an ineffective CD4+ effector response, a down-regulated CD8+ T cell response or a continued, established TH 2 response, each of which could result in an incomplete resolution of the infection (Giambartolomei et al., 2004) . In comparing cytokine responses in patients with acute and chronic brucellosis, before and after treatment, Akbulut et al. (2005) 
BRUCELLA PROTEINS RECOGNIZED IN HUMAN IMMUNE RESPONSES
Epitopes are the molecular subset of any macromolecule recognized by antibodies, B cells, T cells, and NK cells. T cells recognize peptides generally of 8-20 amino acids bound to MHC molecules (HLA Class I associated with CD8+ T cells; HLA Class II associated with CD4+ T cells) presented on the surface of a B cell, macrophage or dendritic cell (Yang et al., 2005) . Non-classical MHC molecules also present non-peptidic epitopes such as glycolipids to non-restricted lymphocytes, particularly NK cells. There are only a few studies in the literature that have demonstrated either a humoral or cellular response to Brucella epitopes. The epitopes of greatest interest to date include Bp26 (a periplasmic protein), Trigger Factor (a chaperone protein; Yang et al., 2005) , and the outer membrane lipoproteins such as Omp 10, 16, and 19 (Tibor et al., 1999) . Interestingly, these antigens, especially the outer membrane lipoproteins, appear to be potent in inducing cytokine responses from memory T cells. In contrast, Brucella LPS and Brucella DNA do not elicit intense immune responses (Giambartolomei et al., 2004; Vrioni et al., 2008) . Previous vaccine studies in mice have used some of these outer membrane epitopes (Pasquevich et al., 2010) as well as certain enzymes such as Cu-Zn superoxide dismutase (Singha et al., 2008 ). Yet, these
were not demonstrated to offer protection for humans or T cell cytokine release assays to prove their efficacy. These antigens have been identified in both B. melitensis and B. abortus. Bp26 and Trigger Factor have been shown to be recognized by the immune system (Yang et al., 2005 ), yet with a reduced activation in patients with chronic/relapsing brucellosis. Recently, Liang et al. (2010 Liang et al. ( , 2011 reported comprehensive systems biology analyses of human antibody responses in acute B. melitensis brucellosis in Peru. A collection of sera isolated from individuals from one of the following groups was used to probe large scale B. melitensis protein microarrays including a ∼1400 proteins array and 3300 proteins array representing nearly the entire encoded proteome: Brucella blood culture positive, blood culture negative with positive Rose Bengal, blood culture negative with negative Rose Bengal, and two naïve groups (from both American and Peruvian individuals.) Sets of proteins that differentiated acutely infected from uninfected patient groups were identified that were recognized by patient IgG responses. These Brucella protein epitopes were then further separated by the patient groups which recognized them, as some were only recognized by culture positive or culture negative patients/Rose Bengal positive patients compared to naïve patients (Table 1) , others cross react in both the culture positive patients and the naïve patients ( Table 2 ) and some antigens produced a positive response in the culture positive group but not the culture negative group/Rose Bengal positive group (Table 3) . This broad spectrum of antibody responses demonstrates the differences between in the manner that these groups respond to Brucella protein epitopes. Interestingly, some of the epitopes mentioned previously (i.e., Bp 26) produced a strong antibody response by Peruvian brucellosis patients, who were culture positive or culture negative patients/Rose Bengal positive patients. These antibody responses could reflect the substantial differences, which these protein epitopes have on the immune system activation, and a large number of antigens recognized by brucellosis patients were identified which have yet to be studied or have limited understanding of their function.
There could be a potential difference in the antibody responses compared to cytokine release assays for these specific epitopes, which produced antibody responses. Based on unpublished data, Bp26, which gave a strong antibody response, does not give a strong TH 1 response; VirB8 does generate a strong TH 1 response, yet does not give a particularly strong antibody response. The use of an epitope database has previously been used for Mycobacteria tuberculosis, and other infections by estimating the immune responses to epitopes associated with a certain organism (Blythe et al., 2007) . A complete cytokine release assay for the entire brucellar proteome has not been undertaken. Based on the fact that antibody production is not protective in chronic brucellosis, we must conclude that T cell assays would be a more appropriate method to pursue with regards to not only diagnostic purposes, but for development of a recombinant protein vaccine as well. analysis of T cell responses associated chronic bacterial, fungal and parasitic infections other than Brucella.
CONCLUSION
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